neurocare's Apollo TMS Therapy systems are now FDA-cleared for the treatment of Obsessive Compulsive Disorder, offering a new non-drug treatment…
Pre-Treatment with blarcamesine entirely prevented Abeta-induced cognitive decline Confirmed significant biomarker-response in hippocampus NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE)…
The Investment is part of BrainsWay’s ongoing strategy to acquire minority positions in leading U.S. mental health providers to help…
Participants Who Complete Treatment in Global Phase 2b PRIZM MELAS Study Are Eligible to EnrollCAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE…
TORBAL DIVISION SALES UP 11%SECURED $10 MILLION IN STRATEGIC DIVESTURE OF GENIE PRODUCT LINEVIVID AND BIOPROCESSING NEW PRODUCT AI ROADMAP…
Calgary, Alberta--(Newsfile Corp. - August 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's…
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the…
Guideline Emphasis on Earlier Treatment to Reduce Health, Dementia Risks Boosts Urgency to Keep Closer Watch on Blood Pressure OMRON…
Advanced 3D model recreates pathological flow conditions to study underlying cerebrovascular disease mechanisms BUSAN, South Korea, Aug. 19, 2025 /PRNewswire/…
Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance…